Guideline supplement: Preterm prelabour rupture of membranes
Table of Contents

1 Introduction ........................................................................................................................................ 3
  1.1 Funding ..................................................................................................................................... 3
  1.2 Conflict of interest .................................................................................................................. 3
  1.3 Summary of change .................................................................................................................. 3

2 Methodology .................................................................................................................................... 4
  2.1 Topic identification ................................................................................................................... 4
  2.2 Scope ......................................................................................................................................... 4
  2.3 Clinical questions ..................................................................................................................... 4
  2.4 Search strategy .......................................................................................................................... 5
    2.4.1 Keywords .......................................................................................................................... 5
  2.5 Consultation ................................................................................................................................. 6
  2.6 Endorsement ............................................................................................................................... 6
  2.7 Publication .................................................................................................................................. 6

3 Levels of evidence ............................................................................................................................ 7
  3.1 Summary recommendations ...................................................................................................... 7

4 Implementation ................................................................................................................................ 8
  4.1 Guideline resources ................................................................................................................... 8
  4.2 Suggested resources .................................................................................................................... 8
  4.3 Implementation measures .......................................................................................................... 8
    4.3.1 QCG measures .................................................................................................................. 8
    4.3.2 Hospital and Health Service measures .............................................................................. 8
  4.4 Quality measures ....................................................................................................................... 9
  4.5 Areas for future research ............................................................................................................ 9
  4.6 Safety and quality ....................................................................................................................... 10

5 References ....................................................................................................................................... 15

Acknowledgements ............................................................................................................................. 16

List of Tables

Table 1. Summary of change .............................................................................................................. 3
Table 2. Scope framework .................................................................................................................. 4
Table 3. Basic search strategy ......................................................................................................... 5
Table 4. Major guideline development processes .......................................................................... 5
Table 5. Levels of evidence and grade of recommendation ............................................................ 7
Table 6. Summary recommendations ............................................................................................... 7
Table 7. NSQHS/EquiP National Criteria .......................................................................................... 10
1 Introduction
This document is a supplement to the Queensland Clinical Guideline (QCG) Preterm prelabour rupture of membranes. It provides supplementary information regarding guideline development, makes summary recommendations, suggests measures to assist implementation and quality activities and summarises changes (if any) to the guideline since original publication. Refer to the guideline for abbreviations, acronyms, flow charts and acknowledgements.

1.1 Funding
The development of this guideline was funded by Healthcare Improvement Unit, Queensland Health. Consumer representatives were paid a standard fee. Other working party members participated on a voluntary basis.

1.2 Conflict of interest
Declarations of conflict of interest were sought from working party members as per the Queensland Clinical Guidelines Conflict of Interest statement. Conflicts of interest were recorded and managed as per usual processes.

1.3 Summary of change
Queensland clinical guidelines are reviewed every 5 years or earlier if significant new evidence emerges. Table 1 provides a summary of changes made to the guidelines since original publication.

Table 1. Summary of change

<table>
<thead>
<tr>
<th>Publication date</th>
<th>Identifier</th>
<th>Summary of major change</th>
</tr>
</thead>
<tbody>
<tr>
<td>December 2018</td>
<td>MN18.48-V1-R23</td>
<td>First publication</td>
</tr>
<tr>
<td>Endorsed by: Statewide Maternity and Neonatal Clinical Network (QLD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>April 2022</td>
<td>MN18.48-V2-R23</td>
<td>Prophylactic antibiotics updated to align with Therapeutic Guidelines recommendations (option for erythromycin monotherapy changed to ‘only if penicillin allergy’)</td>
</tr>
</tbody>
</table>
2 Methodology
Queensland Clinical Guidelines (QCG) follows a rigorous process of guideline development. This process was endorsed by the Queensland Health Patient Safety and Quality Executive Committee in December 2009. The guidelines are best described as ‘evidence informed consensus guidelines’ and draw from the evidence base of existing national and international guidelines and the expert opinion of the working party.

2.1 Topic identification
The topic was identified as a priority following clinician requests and was endorsed by the Queensland Clinical Guidelines Steering committee in 2017.

2.2 Scope
The scope of the guideline was determined using the following framework.

Table 2. Scope framework

<table>
<thead>
<tr>
<th>Scope framework</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Population</strong></td>
<td>Women with a live, singleton, cephalic fetus between 22+0 and 36+6 weeks gestation with suspected prelabour rupture of membranes</td>
</tr>
<tr>
<td><strong>Purpose</strong></td>
<td>Develop an evidence informed clinical guideline on management of PPROM</td>
</tr>
<tr>
<td><strong>Outcome</strong></td>
<td>Guide:</td>
</tr>
<tr>
<td></td>
<td>o Management of pregnant women following PPROM</td>
</tr>
<tr>
<td></td>
<td>o Identification and discussion of the management options following PROM</td>
</tr>
<tr>
<td><strong>Exclusions</strong></td>
<td>Routine antenatal, intrapartum and postpartum care</td>
</tr>
<tr>
<td></td>
<td>Risk factors for PPROM</td>
</tr>
<tr>
<td></td>
<td>Management of:</td>
</tr>
<tr>
<td></td>
<td>o EOGBSD</td>
</tr>
<tr>
<td></td>
<td>o Chorioamnionitis</td>
</tr>
<tr>
<td></td>
<td>o Preterm labour and birth</td>
</tr>
<tr>
<td></td>
<td>o Preterm neonate</td>
</tr>
<tr>
<td></td>
<td>o Women requesting termination of pregnancy following PPROM</td>
</tr>
<tr>
<td></td>
<td>Multiple pregnancy</td>
</tr>
</tbody>
</table>

2.3 Clinical questions
The following clinical questions were generated to inform the guideline scope and purpose:

- How is PROM diagnosed?
- What is the recommended management following PPROM?
- How should ongoing maternal and fetal wellbeing be assessed?
- When is birth indicated following PPROM?
2.4 Search strategy

A search of the literature was conducted between January and August 2018. The QCG search strategy is an iterative process that is repeated and amended as guideline development occurs (e.g. if additional areas of interest emerge, areas of contention requiring more extensive review are identified or new evidence is identified). All guidelines are developed using a basic search strategy. This involves both a formal and informal approach.

Table 3. Basic search strategy

<table>
<thead>
<tr>
<th>Step</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| 1. Review clinical guidelines developed by other reputable groups relevant to the clinical speciality | • This may include national and/or international guideline writers, professional organisations, government organisations, state based groups.  
• This assists the guideline writer to identify:  
  o The scope and breadth of what others have found useful for clinicians and informs the scope and clinical question development  
  o Identify resources commonly found in guidelines such as flowcharts, audit criteria and levels of evidence  
  o Identify common search and key terms  
  o Identify common and key references |
| 2. Undertake a foundation search using key search terms | • Construct a search using common search and key terms identified during Step 1 above  
• Search the following databases  
  o PubMed  
  o CINAHL  
  o Medline  
  o Cochrane Central Register of Controlled Trials  
  o EBSCO  
  o Embase  
• Studies published in English less than or equal to 5 years previous are reviewed in the first instance. Other years may be searched as are relevant to the topic  
• Save and document the search  
• Add other databases as relevant to the clinical area |
| 3. Develop search word list for each clinical question. | • This may require the development of clinical sub-questions beyond those identified in the initial scope.  
• Using the foundation search performed at Step 2 as the baseline search framework, refine the search using the specific terms developed for the clinical question  
• Save and document the search strategy undertaken for each clinical question |
| 4. Other search strategies | • Search the reference lists of reports and articles for additional studies  
• Access other sources for relevant literature  
  o Known resource sites  
  o Internet search engines  
  o Relevant text books |

2.4.1 Keywords

The following keywords were used in the basic search strategy: preterm prelabour rupture of membranes, fetal membranes, PPROM, chorioamnionitis, preterm labour, corticosteroids, magnesium sulfate, rupture of membranes

Other keywords may have been used for specific aspects of the guideline.
2.5 Consultation
Major consultative and development processes occurred between July and September 2018. These are outlined in Table 4.

Table 4. Major guideline development processes

<table>
<thead>
<tr>
<th>Process</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical lead</td>
<td>• The nominated co-clinical leads were approved by QCG Steering Committee</td>
</tr>
<tr>
<td>Consumer participation</td>
<td>• Consumer participation was invited from a range of consumer focused organisations who had previously accepted an invitation for on-going involvement with QCG</td>
</tr>
</tbody>
</table>
| Working party            | • An EOI for working party membership was distributed via email to Queensland clinicians and stakeholders (~2000) in June 2018  
                            • The working party was recruited from responses received  
                            • Working party members who participated in the working party consultation processes are acknowledged in the guideline  
                            • Working party consultation occurred in a virtual group via email |
| Statewide consultation   | • Consultation was invited from Queensland clinicians and stakeholders (~2000) during August 2018  
                            • Feedback was received primarily via email  
                            • All feedback was compiled and provided to the clinical lead and working party members for review and comment |

2.6 Endorsement
The guideline was endorsed by the:
• Queensland Clinical Guidelines Steering Committee in November 2018  
• Statewide Maternity and Neonatal Clinical Network [Queensland] in November 2018

2.7 Publication
The guideline and guideline supplement were published on the QCG website in December 2018  
The guideline can be cited as:

The guideline supplement can be cited as:
3 Levels of evidence

The levels of evidence identified by U.S. Preventive Services Task Force (and contained within the ACOG Practice Bulletin Number 188 Prelabour rupture of membranes) were used to inform the summary recommendations. Levels of evidence and corresponding recommendations are outlined in Table 5. Levels of evidence

Note that the "consensus definition" relates to the clinical experience of the guideline’s clinical leads and working party. Summary recommendations are outlined in Table 6. Summary recommendations

Table 5. Levels of evidence and grade of recommendation

<table>
<thead>
<tr>
<th>Levels of evidence</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Evidence obtained from at least one properly designed randomized controlled trial.</td>
</tr>
<tr>
<td>II-1</td>
<td>Evidence obtained from well-designed controlled trials without randomization.</td>
</tr>
<tr>
<td>II-2</td>
<td>Evidence obtained from well-designed cohort or case–control analytic studies, preferably from more than one center or research group</td>
</tr>
<tr>
<td>II-3</td>
<td>Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments also could be regarded as this type of evidence.</td>
</tr>
<tr>
<td>III-3</td>
<td>Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.</td>
</tr>
<tr>
<td>Consensus*</td>
<td>Opinions based on respected authorities, descriptive studies or reports of expert committees or clinical experience of the working party.</td>
</tr>
</tbody>
</table>

3.1 Summary recommendations

Summary recommendations and levels of evidence are outlined in Table 5.

Table 6. Summary recommendations

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Grading of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Avoid digital examination unless immediate induction is planned as this has been shown to increase the rate of infection</td>
<td>Consensus</td>
</tr>
<tr>
<td>2. If there are no maternal or fetal contraindications, recommend expectant management to women with PPROM before 34+0 weeks gestation</td>
<td>Level A</td>
</tr>
<tr>
<td>3. Recommend antibiotics (as identified in the guideline) to women with PPROM to reduce maternal and neonatal infection</td>
<td>Level A</td>
</tr>
<tr>
<td>4. Recommend antenatal corticosteroids to women with PPROM less than 35+0 weeks gestation</td>
<td>Level A</td>
</tr>
<tr>
<td>5. Recommend intrapartum antibiotic prophylaxis for EOGBSD to women with PPROM</td>
<td>Level A</td>
</tr>
</tbody>
</table>
4 Implementation
This guideline is applicable to all Queensland public and private maternity facilities. It can be downloaded in Portable Document Format (PDF) from www.health.qld.gov.au/qcg

4.1 Guideline resources
The following guideline components are provided on the website as separate resources:

- Education resource: Preterm prelabour rupture of membranes
- Knowledge assessment: Preterm prelabour rupture of membranes
- Parent information: Preterm prelabour rupture of membranes

4.2 Suggested resources
During the development process stakeholders identified additional resources with potential to complement and enhance guideline implementation and application. The following resources have not been sourced or developed by QCG but are suggested as complimentary to the guideline:

- Procedures supporting clinical examination of the woman with PPROM including, abdominal palpation, sterile speculum examination, collection of swabs
- Eligibility criteria for at home care in women with PPROM

4.3 Implementation measures
Suggested activities to assist implementation of the guideline are outlined below.

4.3.1 QCG measures
- Notify Chief Executive Officer and relevant stakeholders
- Monitor emerging new evidence to ensure guideline reflects contemporaneous practice
- Capture user feedback
- Record and manage change requests

4.3.2 Hospital and Health Service measures
Initiate, promote and support local systems and processes to integrate the guideline into clinical practice, including:

- Hospital and Health Service (HHS) Executive endorse the guidelines and their use in the HHS and communicate this to staff
- Promote the introduction of the guideline to relevant health care professionals
- Support education and training opportunities relevant to the guideline and service capabilities
- Align clinical care with guideline recommendations
- Undertake relevant implementation activities as outlined in the Guideline implementation checklist available at www.health.qld.gov.au/qcg
4.4 Quality measures

Auditing of guideline recommendations and content assists with identifying quality of care issues and provides evidence of compliance with the National Safety and Quality Health Service (NSQHS) Standards\(^2\) [Refer to Table 7. NSQHS Standard 1]. Suggested audit and quality measures are identified in Table 8. Clinical quality measures.

Table 7. NSQHS Standard 1

<table>
<thead>
<tr>
<th>NSQHS Standard 1: Clinical governance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical performance and effectiveness</strong></td>
</tr>
<tr>
<td><strong>Criterion 1.27:</strong></td>
</tr>
<tr>
<td>Evidence based care</td>
</tr>
<tr>
<td>b. Support clinicians to use the best available evidence, including relevant clinical care standards developed by the Australian Commission on Safety and Quality in Health Care</td>
</tr>
</tbody>
</table>

The following clinical quality measures are suggested:

Table 8. Clinical quality measures

<table>
<thead>
<tr>
<th>No</th>
<th>Audit criteria</th>
<th>Guideline Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Proportion of women with PPROM who have high vaginal swabs, low vaginal swabs and urine testing at initial presentation</td>
<td>Assessment</td>
</tr>
<tr>
<td>2.</td>
<td>The proportion of expectantly management women with PPROM who receive antibiotic therapy</td>
<td>Initial management</td>
</tr>
<tr>
<td>3.</td>
<td>The proportion of women with PPROM at less than 35+0 weeks gestation who receive antenatal corticosteroids for fetal lung maturity</td>
<td>Prematurity</td>
</tr>
<tr>
<td>4.</td>
<td>The proportion of women with PPROM who receive intrapartum antibiotic EOGBSD prophylaxis</td>
<td>Prematurity</td>
</tr>
</tbody>
</table>

4.5 Areas for future research

During development the following areas where identified as having limited or poor quality evidence to inform clinical decision making. Further research in these areas may be useful.

- Is outpatient management safe for the woman with PPROM?
- At what gestation should active management be routinely recommended to women with PPROM?
- What is the optimal frequency and type of monitoring for women with PPROM?
- When should birth be expedited in women with PPROM between 34+0 and 36+6 weeks
4.6 Safety and quality

In conjunction with the Queensland Clinical Guideline Standard care\(^3\), implementation of this guideline provides evidence of compliance with the National Safety and Quality Health Service Standards.\(^2\)\(^,\)\(^4\)

Table 9. NSQHS/EQuIP National Criteria

<table>
<thead>
<tr>
<th>NSQHS Criteria</th>
<th>Actions required</th>
<th>Evidence of compliance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patient safety and quality systems</strong>&lt;br&gt;Safety and quality systems are integrated with governance processes to enable organisations to actively manage and improve the safety and quality of health care for patients.</td>
<td><strong>Diversity and high risk groups</strong>&lt;br&gt;1.15 The health service organisation:&lt;br&gt;a. Identifies the diversity of the consumers using its services&lt;br&gt;b. Identifies groups of patients using its services who are at higher risk of harm&lt;br&gt;c. Incorporates information on the diversity of its consumers and higher-risk groups into the planning and delivery of care</td>
<td>✔️ Assessment and care appropriate to the cohort of patients is identified in the guideline&lt;br&gt;✔️ High risk groups are identified in the guideline&lt;br&gt;✔️ The guideline is based on the best available evidence</td>
</tr>
<tr>
<td><strong>Clinical performance and effectiveness</strong>&lt;br&gt;The workforce has the right qualifications, skills and supervision to provide safe, high-quality health care to patients.</td>
<td><strong>Evidence based care</strong>&lt;br&gt;1.27 The health service organisation has processes that:&lt;br&gt;a. Provide clinicians with ready access to best-practice guidelines, integrated care pathways, clinical pathways and decision support tools relevant to their clinical practice&lt;br&gt;b. Support clinicians to use the best available evidence, including relevant clinical care standards developed by the Australian Commission on Safety and Quality in Health Care</td>
<td>✔️ Queensland Clinical Guidelines is funded by Queensland Health to develop clinical guidelines relevant to the service line to guide safe patient care across Queensland&lt;br&gt;✔️ The guideline provides evidence-based and best practice recommendations for care&lt;br&gt;✔️ The guideline is endorsed for use in Queensland Health facilities.&lt;br&gt;✔️ A desktop icon is available on every Queensland Health computer desktop to provide quick and easy access to the guideline</td>
</tr>
<tr>
<td><strong>Patient safety and quality systems</strong>&lt;br&gt;Safety and quality systems are integrated with governance processes to enable organisations to actively manage and improve the safety and quality of health care for patients.</td>
<td><strong>Policies and procedures</strong>&lt;br&gt;1.7 The health service organisation uses a risk management approach to:&lt;br&gt;a. Set out, review, and maintain the currency and effectiveness of, policies, procedures and protocols&lt;br&gt;b. Monitor and take action to improve adherence to policies, procedures and protocols&lt;br&gt;c. Review compliance with legislation, regulation and jurisdictional requirements</td>
<td>✔️ QCG has established processes to review and maintain all guidelines and associated resources&lt;br&gt;✔️ Change requests are managed to ensure currency of published guidelines&lt;br&gt;✔️ Implementation tools and checklist are provided to assist with adherence to guidelines&lt;br&gt;✔️ Suggested audit criteria are provided in guideline supplement&lt;br&gt;✔️ The guidelines comply with legislation, regulation and jurisdictional requirements</td>
</tr>
</tbody>
</table>
### NSQHS Criteria

#### Actions required

**Communication that supports effective partnerships**

- 2.8 The health service organisation uses communication mechanisms that are tailored to the diversity of the consumers who use its services and, where relevant, the diversity of the local community.
- 2.9 Where information for patients, carers, families and consumers about health and health services is developed internally, the organisation involves consumers in its development and review.

**Partnerships in healthcare governance planning, design, measurement and evaluation**

- 2.11 The Health service organisation:
  - a. Involves consumers in partnerships in the governance of, and to design, measure and evaluate, health care.
  - b. Has processes so that the consumers involved in these partnerships reflect the diversity of consumers who use the service, or, where relevant, the diversity of the local community.

**Integrating clinical governance**

- 4.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when:
  - a. Implementing policies and procedures for medication management.
  - b. Managing risks associated with medication management.
  - c. Identifying training requirements for medication management.

#### Evidence of compliance

- Consumer consultation was sought and obtained during the development of the guideline. Refer to the acknowledgement section of the guideline for details.
- Consumer information is developed to align with the guideline and included consumer involvement during development and review.
- The consumer information was developed using plain English and with attention to literacy and ease of reading needs of the consumer.
- Consumers are members of guideline working parties.
- The guideline is based on the best available evidence.
- The guidelines and consumer information are endorsed by the QCG and Queensland Statewide Maternity and Neonatal Clinical Network Steering Committees which includes consumer membership.
- The guideline provides current evidence based recommendations about medication.
<table>
<thead>
<tr>
<th>NSQHS Criteria</th>
<th>Actions required</th>
<th>Evidence of compliance</th>
</tr>
</thead>
</table>
| **NSQHS Standard 5: Comprehensive care**<br>Clinical governance and quality improvement to support comprehensive care<br>Systems are in place to support clinicians to deliver comprehensive care | Integrating clinical governance 5.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when:<br>a. Implementing policies and procedures for comprehensive care  
b. Managing risks associated with comprehensive care  
c. Identifying training requirements to deliver comprehensive care  
Partnering with consumers 5.3 Clinicians use organisational processes from the Partnering with Consumers Standard when providing comprehensive care to:<br>a. Actively involve patients in their own care  
b. Meet the patient’s information needs  
c. Share decision-making | ☑️ The guideline has accompanying educational resources to support ongoing safety and quality education for identified professional and personal development. The resources are freely available on the internet [www.health.qld.gov.au/qcg](http://www.health.qld.gov.au/qcg)  
☑️ The guideline provides evidence-based and best practice recommendations for care  
☑️ Consumer information is developed for the guideline |

| NSQHS Standard 6: Communicating for safety | Integrating clinical governance 6.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when:<br>a. Implementing policies and procedures to support effective clinical communication  
b. Managing risks associated with clinical communication  
c. Identifying training requirements for effective and coordinated clinical communication  
Partnering with consumers 6.3 Clinicians use organisational processes from the Partnering with Consumers Standard to effectively communicate with patients, carers and families during high-risk situations to:<br>a. Actively involve patients in their own care  
b. Meet the patient’s information needs  
c. Share decision-making  
Organisational processes to support effective communication 6.4 The health service organisation has clinical communications processes to support effective communication when:<br>a. Identification and procedure matching should occur  
b. All or part of a patient’s care is transferred within the organisation, between multidisciplinary teams, between clinicians or between organisations; and on discharge  
c. Critical information about a patient’s care, including information on risks, emerges or changes | ☑️ Requirements for effective clinical communication by clinicians are identified  
☑️ The guideline provides evidence-based and best practice recommendations for communication between clinicians  
☑️ The guideline provides evidence-based and best practice recommendations for communication with patients, carers and families  
☑️ The guideline provides evidence-based and best practice recommendations for discharge planning and follow-up care |
<table>
<thead>
<tr>
<th>NSQHS Criteria</th>
<th>Actions required</th>
<th>Evidence of compliance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Communication of critical information</strong></td>
<td><strong>Communicating critical information</strong></td>
<td>☑️ Requirements for effective clinical communication of critical information are identified</td>
</tr>
<tr>
<td>Systems to effectively communicate critical information and risks when they emerge or change are used to ensure safe patient care.</td>
<td>6.9 Clinicians and multidisciplinary teams use clinical communication processes to effectively communicate critical information, alerts and risks, in a timely way, when they emerge or change to: a. Clinicians who can make decisions about care b. Patients, carers and families, in accordance with the wishes of the patient</td>
<td>☑️ Requirements for escalation of care are identified</td>
</tr>
<tr>
<td><strong>Correct identification and procedure matching</strong></td>
<td><strong>Correct identification and procedure matching</strong></td>
<td>☑️ Requirements for safe and for correct patient identification are identified</td>
</tr>
<tr>
<td>Systems to maintain the identity of the patient are used to ensure that the patient receives the care intended for them.</td>
<td>6.5 The health service organisation: a. Defines approved identifiers for patients according to best-practice guidelines b. Requires at least three approved identifiers on registration and admission; when care, medication, therapy and other services are provided; and when clinical handover, transfer or discharge documentation is generated</td>
<td></td>
</tr>
<tr>
<td><strong>Communicating at clinical handover</strong></td>
<td><strong>Clinical handover</strong></td>
<td>☑️ The guideline acknowledges the need for local protocols to support transfer of information, professional responsibility and accountability for some or all aspects of care</td>
</tr>
<tr>
<td>Processes for structured clinical handover are used to effectively communicate about the health care of patients.</td>
<td>6.7 The health service organisation, in collaboration with clinicians, defines the: a. Minimum information content to be communicated at clinical handover, based on best-practice guidelines b. Risks relevant to the service context and the particular needs of patients, carers and families c. Clinicians who are involved in the clinical handover 6.8 Clinicians use structured clinical handover processes that include: a. Preparing and scheduling clinical handover b. Having the relevant information at clinical handover c. Organising relevant clinicians and others to participate in clinical handover d. Being aware of the patient’s goals and preferences e. Supporting patients, carers and families to be involved in clinical handover, in accordance with the wishes of the patient f. Ensuring that clinical handover results in the transfer of responsibility and accountability for care</td>
<td></td>
</tr>
<tr>
<td>NSQHS Criteria</td>
<td>Actions required</td>
<td>Evidence of compliance</td>
</tr>
<tr>
<td>----------------</td>
<td>-----------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>NSQHS Standard 8: Recognising and responding to acute deterioration</td>
<td><strong>Integrating clinical governance</strong>&lt;br&gt;8.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when:&lt;br&gt;a. Implementing policies and procedures for recognising and responding to acute deterioration&lt;br&gt;b. Managing risks associated with recognising and responding to acute deterioration&lt;br&gt;c. Identifying training requirements for recognising and responding to acute deterioration&lt;br&gt;<strong>Partnering with consumers</strong>&lt;br&gt;8.3 Clinicians use organisational processes from the Partnering with Consumers Standard when recognising and responding to acute deterioration to:&lt;br&gt;a. Actively involve patients in their own care&lt;br&gt;b. Meet the patient's information needs&lt;br&gt;c. Share decision-making&lt;br&gt;<strong>Recognising acute deterioration</strong>&lt;br&gt;8.4 The health service organisation has processes for clinicians to detect acute physiological deterioration that require clinicians to:&lt;br&gt;a. Document individualised vital sign monitoring plans&lt;br&gt;b. Monitor patients as required by their individualised monitoring plan&lt;br&gt;c. Graphically document and track changes in agreed observations to detect acute deterioration over time, as appropriate for the patient</td>
<td>✓ The guideline is consistent with National Consensus statements recommendations&lt;br&gt;✓ The guideline recommends use of tools consistent with the principles of recognising and responding to clinical deterioration&lt;br&gt;✓ Consumer information is developed for the guideline</td>
</tr>
</tbody>
</table>
5 References

Acknowledgements
Queensland Clinical Guidelines gratefully acknowledge the contribution of Queensland clinicians and other stakeholders who participated throughout the guideline development process particularly:

Working Party Clinical Lead
Dr Yogesh Chadha, Obstetrician and Gynaecologist, Royal Brisbane and Women’s Hospital
Ms Rhonda Taylor, Midwifery Consultant, Birth Suite/Birth Centre, The Townsville Hospital

QCG Program Officer
Ms Jacinta Lee

Working party membership
Dr Elize Bolton, Clinical Director, Bundaberg Hospital
Dr Paul Bretz, Obstetrician and Gynaecologist, Mater Health Services
Ms Lynne Buetow, Midwife, Acting Midwifery Educator, Royal Brisbane and Women’s Hospital
Dr Pinar Cingiloglu, Principal House Officer, Royal Brisbane and Women’s Hospital
Ms Eileen Cooke, Consumer Representative, Preterm Infants Parents Assoc. Inc. (PIPA)
Ms Racheal Dennis, Midwife, The Townsville Hospital
Mrs Carole Dodd, Registered Midwife/Clinical Nurse, Caboolture Hospital
Dr Siew Goh, Principal House Officer, Bundaberg Hospital
Dr Leigh Grant, Senior Medical Officer, Rockhampton Hospital
Ms Louise Homan, Midwife, Atherton Hospital
Dr Shveta Kapoor, Obstetrician Gynaecologist, Ipswich Hospital
Ms Meredith Lovegrove, Eligible Private Practice Midwife, My Midwives Brisbane North
Dr Rebecca Mitchell, Senior Registrar, Cairns Hospital
Dr Aruna Munasinghe, Principal House officer, Rockhampton Hospital
Dr Saliya Ovitigalage, Staff Specialist, Hervey Bay Hospital
Dr Thangeswaran Rudra, Senior Staff Specialist, Royal Brisbane and Women’s Hospital
Mrs Valerie Slavin, Midwife and Research Midwife, Gold Coast University Hospital
Dr Joseph Thomas, Senior Specialist, Mater Health Services
Mrs Gigi Tony, Registered Midwife, Mater Mothers’ Hospital
Dr Lilantha Wedisinghe, Staff Specialist, Rockhampton Hospital

Queensland Clinical Guidelines Team
Associate Professor Rebecca Kimble, Director,
Ms Jacinta Lee, Manager,
Ms Stephanie Sutherns, Clinical Nurse Consultant,
Ms Cara Cox, Clinical Nurse Consultant,
Dr Brent Knack, Program Officer,
Mr Majid Shams Nosrati, Senior Technical and Administration Officer,
Steering Committee,